Search research articles
Contact Us
Filters
Showing results (161-170 of 189) with videos related to
Page
of 19
Sort By:
Haematologica
|
April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
Maximilian Merz, Hans Salwender, Mathias Haenel, et al.
Leukemia
|
May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Hans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Journal of Hematology & Oncology
|
December 13, 2023
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers
Anja Seckinger, Sara Majocchi, Valéry Moine, et al.
Hematology (Amsterdam, Netherlands)
|
February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
Hans Salwender, Niels Weinhold, Axel Benner, et al.
International Journal of Molecular Sciences
|
June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries
Anja Seckinger, Hans Salwender, Hans Martin, et al.
Journal of Hematology & Oncology
|
December 19, 2024
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Dirk Hose, Seemun Ray, Sina Rößler, et al.
BMC Cancer
|
May 30, 2019
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
Hans Salwender, Uta Bertsch, Katja Weisel, et al.
Journal of Hematology & Oncology
|
January 25, 2025
Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Dirk Hose, Seemun Ray, Sina Rößler, et al.
Haematologica
|
December 7, 2014
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells
Niels Weinhold, Tobias Meissner, David C Johnson, et al.
Leukemia
|
July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Elias K Mai, Kaya Miah, Uta Bertsch, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 189) with videos related to
Sort By:
Page
of 19
Haematologica
|
April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
Maximilian Merz, Hans Salwender, Mathias Haenel, et al.
Leukemia
|
May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Hans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Journal of Hematology & Oncology
|
December 13, 2023
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers
Anja Seckinger, Sara Majocchi, Valéry Moine, et al.
Hematology (Amsterdam, Netherlands)
|
February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
Hans Salwender, Niels Weinhold, Axel Benner, et al.
International Journal of Molecular Sciences
|
June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries
Anja Seckinger, Hans Salwender, Hans Martin, et al.
Journal of Hematology & Oncology
|
December 19, 2024
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Dirk Hose, Seemun Ray, Sina Rößler, et al.
BMC Cancer
|
May 30, 2019
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
Hans Salwender, Uta Bertsch, Katja Weisel, et al.
Journal of Hematology & Oncology
|
January 25, 2025
Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Dirk Hose, Seemun Ray, Sina Rößler, et al.
Haematologica
|
December 7, 2014
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells
Niels Weinhold, Tobias Meissner, David C Johnson, et al.
Leukemia
|
July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Elias K Mai, Kaya Miah, Uta Bertsch, et al.
Page
of 19